Sangamo Names Amgen’s D. Mark McClung as Chief Business Officer

Sangamo Therapeutics (NASDAQ: [[ticker:SGMO]]) has appointed D. Mark McClung as executive vice president and chief business officer. Previously McClung was general manager of global oncology commercial at Amgen (NASDAQ: [[ticker:AMGN]]), which he joined from Onyx Pharmaceuticals (acquired by Amgen for about $10 billion in 2013). For two decades prior, he held roles at GlaxoSmithKline (NYSE: [[ticker:GSK]]), including head of global commercial for GSK Oncology.

The Brisbane, CA-based biotech’s first product candidate, an investigational gene therapy for hemophilia A licensed to Pfizer (NYSE: [[ticker:PFE]]), is poised to enter Phase 3 testing this year. Sangamo’s pipeline includes experimental gene therapy, cell therapy, genome editing and gene regulation treatments.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine. View all posts by Sarah de Crescenzo